Co-Grown - an exciting biodesign opportunity to work with our lab and our collaborators on materials that grow with self-pigmentation. See below for competition details.

wait what how does the first lady of china speak better american than the first lady of america

Strongly agree, for many research applications you're literally doing something for the first time anyone ever has. The fixed effort of making it robotic far exceeds the marginal benefit. Still in a lot of bio there are core protocols that are repeated a lot in different contexts

There's going to be so much cheap lab automation equip. on LabX in 2 to 3 years, when either all these new self-driving AI wetlabs fold, or they realise that current lab automation equip. sucks for what they need to do.

Direct cell-to-cell transmission of retrotransposons: cell.com/cell/fulltext/S0092…

$451 million into two AI biotech companies in a single morning. @enveda closed a $311M Series E led by @CatalioCapital. Their PRISM platform identifies biologically active molecules made by plants, microbes, and the human body, then ranks them by therapeutic potential so Enveda's chemists can turn the best ones into oral medicines. Since 2019 that approach has produced 17 development candidates, three now in human trials. Two of those read out positively this year. ENV-294 improved eczema severity by 85% on average after 42 days in Phase 1b, with more data coming at EADV on October 1. ENV-308, based on a molecule the body releases during intense exercise, was well tolerated in 88 volunteers with a very clean GI profile, and it's being developed to help people keep weight off after stopping GLP-1s. ENV-6946 for inflammatory bowel disease is in Phase 1. Enveda has now raised more than $845M total, and @georgecpetro of Catalio joins the board. The syndicate is basically a who's who across tech and healthcare: Durable Capital Partners, ICONIQ, @lightspeedvp, Surveyor Capital, @TRowePrice, Digitalis Ventures, Alderline Group, and a sovereign wealth fund as new investors, alongside existing backers @BaillieGifford, @PremjiInvest, FPV Ventures, @trueventures, @KinnevikAB, Dimension, Lifeforce Capital, and @Lux_Capital. Alex Gorsky, former J&J CEO and now at ICONIQ and Alderline, is part of it too. @Basecamp_Res closed an oversubscribed $140M Series C led by @S32_VC, with Andy Conrad, former CEO of Verily, joining the board. Their EDEN models are trained on the Trillion Gene Atlas, biological data collected through benefit-sharing partnerships in more than 30 countries and built with partners including @nvidia, @AnthropicAI, @PacBio, and Ultima Genomics. First target is in vivo cell therapy: pairing EDEN-designed DNA with large serine recombinases to write complex sequences into a patient's cells inside the body, which could take a lot of the cost out of today's cell therapies. André Hoffmann, Vice-Chairman of @Roche, invested personally, and Richard Pearce joins from @biogen as Chief Business Officer. That round brought in Anthology Fund, @CatalioCapital, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, @nvidia, PostScriptum, Redalpine, @RockefellerFdn, Singular, Sovereign AI, and @trueventures. Reading the two announcements back to back, both companies are built on the same bet. The best starting material for new medicines is what evolution already made, and AI can finally read it at scale. Enveda cites an estimate that 99% of nature's chemical diversity has never been examined. That's the part I keep coming back to. Also kind of wild: Catalio and True Ventures are in both rounds, announced the same day. Congratulations to @viswacolluru, Nadeem Sarwar, Michael Charlton, Doug Maslin, Soumoditya Dey, and the whole Enveda team, and to @glen_gowers, Richard Pearce, and everyone at Basecamp Research.

Neat but not that exciting. Claude did lots of tedious sequence inspection and identified some probably-functional biology in a poorly-studied bacteriophage. There are many such systems, no evidence this one is worth the effort needed to make it into "the next CRISPR" or anything

Use reward-guided search in a generative model's latent space to design high-affinity protein binders to proteins and carbohydrates. @DidiKieran @sacdallago @karsten_kreis @ArashVahdat @PierceOgdenJ

"Fire amoeba" found in hot spring breaks heat tolerance record, as it's able to survive temperatures up to 158F (70C)--the highest of any complex organism. Learn more in Cell: cell.com/cell/fulltext/S0092… Angela M. Oliverio & colleagues @CellCellPress

First they came for SWE…then they came for the mathematicians…then they came for Arc Institute…

sorry I didn't attend your event, i'm child time maxing.

Breaking: @Pioneer__Labs has engineered a microbe able to live on Mars, consuming solely nutrients found on the planet to create building materials. I interviewed @erika_alden_d, the CEO, to learn how they did it and what might come next. Much of the interview was about bottlenecks to growing life on Mars; the planet has tons of water, but only in the form of ice. (If you melted all that ice, it would create an ocean 100 feet deep across the entire planet!) Similarly, we talked about the dirt. Martian regolith has salts, heavy metals, and perchlorates that are toxic to many organisms. Some microbes on Earth are able to break down these toxins, though, so Pioneer is engineering them to make them better at eating those toxins while adding nutrients back into the soil. This could possibly help support plant life in the future. Watch the full episode and subscribe to @AsimovPress for more. 0:00 A first microbe engineered for Mars 5:03 Simulating Martian chemistry 8:27 The five "pioneer species" 17:20 Water, warming, and nitrogen 26:39 Radiation, growth rates, and poor measurements 35:49 Starship 41:05 Why create a second biosphere?

Josie's List of Bio "Millenium" Problems Tldr: 1. Next gen Bio manufacturing/bioreactors 2. Neurotech/neural decoding/non-invasive millions+ channel recording 3. Scalable embryo creation 4. Be able to create and modify megabases of DNA 5. Mammalian biological chassis/model 6. Non-polyploid crops/plants 7. Understand polygenic traits 8. < $1 genome sequencing at scale 9. Non-viral gene therapy that works 10. Artificial womb Runners up 11. Cell from scratch 12. Haploid eukaryotic model organism 1. Next gen Bio manufacturing/bioreactors - right now its really expensive to produce biologics. People grow yeast that have been genetically modified in giant steel vats to try and make significant quantities of drugs and chemicals. It sucks. Building the bioreactors are expensive, the production doesn't scale. There are so many issues with it. We still can't even come close to producing the amount of meat cattle can for the time and price, the amount of thc cannabis can produce or any of the other number of cellular phenomena. Biology is good at scaling but we suck at scaling biology. We need better bio manufacturing and companies like Buzz Bio using soldier fly larva and others using mycelium and chicken eggs are probably going to be the future. 2. Neurotech/neural decoding/non-invasive millions+ channel recording - My big three in bio are probably: understanding genetics, developmental biology and the brain. We figure those out we will have a pretty amazing command of the living world. So many applications and glad lots of smart people are working on this.

you should start a biology research institution going after your own personal millennium problem. there has literally never been a better time

Genomes are full of dark matter of unknown functions. We present Minerva, a new method for discovery guided by genome language models. Minerva reveals the interactions hidden in non-coding DNA, pointing to hundreds of new putative RNAs and repetitive elements per bacterial genome. Minerva allows us to find and study elements invisible to traditional methods at orders of magnitude greater scale than before.

Europe’s largest bacterial cellulose plant is coming to Germany. @BIOWEG_UG plans to produce up to 10,000 tonnes annually of biodegradable ingredients made from local industrial side streams, with construction beginning in Q4 2026 and commercial volumes expected in 2028. ilbioeconomista.com/2026/09/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬 syntheticbiologysummit.com/?…

going between any two points in london takes 54 mins